DIENOGEST

Dienogest is a synthetic progestin, often used in combination with estrogen in contraceptive pills and for the treatment of endometriosis. It was developed as a more selective progestin, aiming to provide effective contraception while minimising side effects. Dienogest was first approved by regulatory agencies in the early 2000s for the treatment of endometriosis and later for use in birth control formulations. Its unique progestogenic action has made it a preferred option for treating conditions like endometriosis and heavy menstrual bleeding.

Dienogest is primarily prescribed for the following conditions: Endometriosis : It helps alleviate symptoms like pelvic pain and dysmenorrhea (painful periods) by reducing endometrial lesions and the associated inflammation. Contraception : When combined with estrogen, dienogest is used in birth control pills to prevent ovulation and reduce the chances of pregnancy. Menstrual Disorders : It is also used to treat irregular or heavy menstrual bleeding by stabilising the endometrial lining and regulating menstrual cycles.

Dienogest is available in oral tablet form and is typically administered once daily. The dosage varies depending on the condition being treated: For endometriosis, the standard dose is 2 mg per day, taken continuously without a break. In combination contraceptives, the dosage of dienogest may be part of a combined regimen with estrogen, and it’s typically taken for 21 days, followed by a 7-day break. The tablet should be taken with a glass of water, and it can be taken with or without food.

Like all medications, dienogest can cause side effects. Common side effects include: Headache : Hormonal changes may trigger headaches or migraines. Mood Changes : Some users may experience changes in mood, including depression or irritability. Breast Tenderness : Hormonal therapies often cause breast discomfort or tenderness. Weight Changes : A small percentage of users may experience weight gain. Acne : Though less common than with other progestins, some women may develop acne. Ovarian Cysts : The use of dienogest, especially for long periods, may increase the risk of ovarian cysts, although most are benign.

Pregnancy : Dienogest should not be used during pregnancy. If pregnancy is suspected, it is crucial to stop the medication and consult a healthcare provider. Liver Disorders : Patients with a history of liver diseases should exercise caution as dienogest can affect liver function. Regular monitoring of liver enzymes is recommended. Cardiovascular Health : Women with a history of thromboembolic events, such as deep vein thrombosis (DVT) or pulmonary embolism, should not use dienogest. Breast Cancer : There is limited evidence suggesting an increased risk of breast cancer with prolonged use of progestins, including dienogest. Any breast abnormalities should be promptly evaluated.

Monitoring : Regular follow-up with a healthcare provider is important, especially in women with conditions like diabetes, high blood pressure, or liver disease. Drug Interactions : Some medications, such as anticonvulsants and antibiotics, may reduce the efficacy of dienogest. Always inform your doctor about any other medications being taken. Bleeding Irregularities : Spotting or breakthrough bleeding is common during the first few months of treatment, especially when dienogest

Dienogest should always be used under the guidance of a healthcare provider. It is crucial to take the medication consistently, as missing doses can reduce its effectiveness. Women with a history of liver disease or blood clots should consider alternative treatments. Always check with your doctor if you experience unusual symptoms such as severe abdominal pain, leg swelling, or chest pain.

Lee J, Park HJ, Yi KW. Dienogest in endometriosis treatment: A narrative literature review. Clin Exp Reprod Med. https://pmc.ncbi.nlm.nih.gov/articles/PMC10711247/ El Taha L, Abu Musa A, Khalifeh D, Khalil A, Abbasi S, Nassif J. Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2021 Dec;267:205-212. https://pubmed.ncbi.nlm.nih.gov/34826668/ https://www.sciencedirect.com/science/article/abs/pii/S0301211510001715